This 13-episode MinuteCE program examines contemporary treatment selection in inflammatory bowel disease, with emphasis on aligning therapy choice with disease phenotype, severity, prognosis, treatment goals, safety considerations, and patient-specific factors. Episodes cover conventional agents, anti-TNF therapies, gut-selective anti-integrins, IL-12/23 and IL-23 pathway inhibitors, JAK inhibitors, and S1P modulators, with attention to practical positioning in ulcerative colitis and Crohn’s disease. The program also discusses treat-to-target care, including STRIDE/STRIDE-II principles, and uses case-based segments to examine how comorbidities, extraintestinal manifestations, prior treatment failure, infection risk, pregnancy planning, and guideline-based care inform individualized IBD management.
Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 2.0.
IBD Care Reimagined: Personalized, Proactive, and Target-Driven Management
Overview
Disclosure of Relevant Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence, it is the policy of Global Learning Collaborative (GLC) that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. GLC has full policies in place that have identified and mitigated financial relationships and conflicts of interest to ensure independence, objectivity, balance, and scientific accuracy prior to this educational activity.
The following faculty/staff members have reported financial relationships with ineligible companies within the last 24 months.
Chair:
David T. Rubin, MD
Joseph B. Kirsner Professor of Medicine
Director, Inflammatory Bowel Disease Center
University of Chicago
Chicago, IL
Advisor/Consultant: AbbVie, Abivax SA, AltruBio, Athos Therapeutics, Inc., Bristol Myers Squibb, Celltrion, Connect Biopharma, Eli Lilly & Co., Genentech (Roche) Inc., Iterative Health, Janssen Pharmaceuticals, Johnson & Johnson, Merck & Co., Mirador, Odyssey Therapeutics, Pfizer, Sanofi, Spyre, Takeda Pharmaceuticals, Vedanta Biosciences, Ventyx
Contracted Researcher: Takeda Pharmaceuticals
Faculty:
Michael Dolinger, MD, MBA
Director of Pediatric IBD
Department of Pediatrics
NYU Langone Health
NYU Grossman School of Medicine
New York, NY
Ownership interest: Dova Health
Consulting Fees: AbbVie, Celltrion, Johnson & Johnson, Neurologica Corp. (a subsidiary of Samsung Electronics Co., Ltd.), Pfizer, Sanofi, Takeda
Sharon Dudley-Brown, PhD, FNP-BC
Division of Gastroenterology & Hepatology
Department of Medicine
Johns Hopkins University
Baltimore, MD
Consulting Fees: AbbVie, Janssen (Johnson & Johnson), Takeda
Ugo Iroku, MD, MHS
Assistant Professor of Clinical Medicine
Icahn School of Medicine at Mount Sinai
Gastroenterologist, Summit Health
New York, NY
Consulting Fees: AbbVie, Johnson & Johnson
Florence-Damilola Odufalu, MD
Assistant Professor of Clinical Medicine
Keck School of Medicine
University of Southern California
Los Angeles, CA
Consulting Fees: AbbVie, Janssen, Johnson & Johnson, Pfizer
Reviewers/Content Planners/Authors:- Tim Person has no relevant relationships to disclose.
- Parul Yadav, MD, has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Compare the efficacy and safety profiles of conventional, biologic, and small-molecule agents used in the treatment of IBD
- Evaluate data on emerging therapies in IBD
Target Audience
This activity has been designed to meet the educational needs of clinical gastroenterologists and advanced practice providers as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare professionals involved in managing patients with inflammatory bowel disease (IBD).
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) and Crohn’s & Colitis Foundation are jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 2.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 2.0 contact hour(s)/0.2 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-26-071-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credit(s). Approval is valid until 6/1/27. PAs should claim only the credit commensurate with the extent of their participation in the activity. Provider(s)/Educational Partner(s)
Global Learning Collaborative (GLC) designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. GLC’s methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.Commercial Support
This activity is supported by independent educational grants from AbbVie, Inc., Genentech, Inc., Johnson & Johnson, and Takeda Pharmaceuticals U.S.A., Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date: Ongoing Program - Expiration date will be posted when all episodes are published.
